NEW in CME Courses: Improving Healthcare Delivery in Immuno-Oncology: A Global Quality Improvement Initiative-Module 1

 Expand your knowledge of quality improvement tools and strategies

Target Audience: Oncologists; Hematologists; Hematologist/Oncologists

 

The introduction of immune checkpoint inhibitors has resulted in a paradigm shift for the management of many historically difficult-to-treat malignancies. Although these agents are improving outcomes for patients, their use in clinical practice is slowed by a set of unique practical challenges, including effective patient selection, assessment of response, and management of immune-related adverse events (irAEs). Moreover, divergent guidelines for differing tumor types further complicate the optimal use of these agents.

This highly interactive activity, the first in a series of three, is designed to take you on a journey with the I.D.L. Oncology Group, a “virtual” oncology practice, as it begins a quality improvement (QI) initiative focused on the use of checkpoint inhibitor therapy. As you follow along with the oncology group’s journey of developing and implementing this quality initiative you will also learn about best practices in the use of checkpoint inhibitor therapy, as well as the tenets of QI.

This activity – Improving Healthcare Delivery in Immuno-Oncology: A Global Quality Improvement Initiative-Module 1​, offers: 1.5 AMA PRA Category 1 Credits™.

Click here to start this activity!